



Value Added Medicines

What value repurposed medicines might bring to hospital pharmacists

Satellite symposium
EAHP Congress, Cannes
22 March 2017

patients • quality • value • sustainability • partnership




Value Added Medicines Group Membership

MEMBERS
ASSOCIATIONS



Pressure on EU budgets Reduction of healthcare spending




Average annual growth in pharmaceutical expenditure¹ per capita, in real terms, 2005-09 and 2009-13 (or nearest periods)

patients • quality • value • sustainability • partnership



New approaches are needed If we want to preserve universal health coverage

Global spending on new brand medicines has more than doubled in 2014 and is 2.6% of global pharmaceutical spending



patients • quality • value • sustainability • partnership



Healthcare system efficiency

Finding new ways to deliver better health & access

20-40% of healthcare spending are allocated to unnecessary or non cost-effective services



Source: Toumi M & Rémuzat C (2016) Value Added Medicines – Rethink, Reinvent & Optimize Medicines, Improving Patient Health & Access
patients • quality • value • sustainability • partnership



Future opportunities


Delivering better health & sustainable access

Suboptimal use of drugs represent opportunities to rethink and optimise current health delivery systems as well as reinvent current therapies

patients • quality • value • sustainability • partnership



Value added medicines Rethink, reinvent & optimise medicines



Benefits for healthcare community





Value Added Medicines Group

Our Mission

Bring innovation continuously throughout a molecule's lifecycle, particularly those molecules no longer protected by patent.



However, to combine new technologies with known molecules requires considerable R&D investment and effort.

The ambition of the **Value Added Medicines Group** is to play a leading role in unlocking untapped research potential, focusing on existing molecules, by establishing a sustainable market model that incentivises R&D and access to value added medicines in Europe to patients who need it.

patients • quality • value • sustainability • partnership



Call for action

From cost focus to outcomes focus



- Stakeholders already recognize the benefit of value added medicines
- **Open pathways for value added medicines**
Adapt HTA and P&R pathways so that benefits can be shown and rewarded appropriately
- **Industry proactive approach**
Work together with all concerned stakeholders to discuss and develop innovative ways to generate required evidence & communicate on benefits

patients • quality • value • sustainability • partnership



Partnership

Improving well-being, keeping people healthy & delivering the most efficient care

Policy makers, payers, patients and healthcare professionals and our sector group need to work together to address the barriers

patients • quality • value • sustainability • partnership



Agenda

VALUE ADDED MEDICINES



What value repurposed medicines might bring to hospital pharmacists

AGENDA

Time	Topic	Speaker
16:15 – 16:30	Introduction to value added medicines	Christoph Stofer
16:30 – 16:55	Importance of continuous innovation – Perspective of a healthcare professional	Stephan Krähenbühl
16:55 – 17:25	Valued added medicines: relevance for hospital pharmacists and how to ensure their availability	Minodora Voiculescu
17:25 – 17:45	Expert discussion	

patients • quality • value • sustainability • partnership

Speakers

Stephan Krähenbühl	Minidora Voiculescu
	
University Hospital Basel Switzerland	Medical Advisor, Fresenius Kabi Germany

patients • quality • value • sustainability • partnership